China Shineway Pharmaceutical Group Limited (2877.HK)
HKD 9.43
(-1.26%)
HKD 9.43
(-1.26%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.42 Billion CNY | 60.49% |
| 2022 | 1.1 Billion CNY | 25.97% |
| 2021 | 903.74 Million CNY | 13.39% |
| 2020 | 620.03 Million CNY | -7.56% |
| 2019 | 672.7 Million CNY | -2.75% |
| 2018 | 691.76 Million CNY | 14.78% |
| 2017 | 602.71 Million CNY | -20.24% |
| 2016 | 778.67 Million CNY | -2.7% |
| 2015 | 776.63 Million CNY | -8.07% |
| 2014 | 844.84 Million CNY | 7.21% |
| 2013 | 788.03 Million CNY | 4.04% |
| 2012 | 757.44 Million CNY | -25.39% |
| 2011 | 1.01 Billion CNY | 1.84% |
| 2010 | 1.04 Billion CNY | 12.87% |
| 2009 | 883.19 Million CNY | 84.17% |
| 2008 | 479.55 Million CNY | 19.65% |
| 2007 | 400.78 Million CNY | 8.18% |
| 2006 | 370.46 Million CNY | 5.84% |
| 2005 | 350.03 Million CNY | 15.82% |
| 2004 | 302.23 Million CNY | 46.55% |
| 2003 | 206.23 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q4 | 463.87 Million CNY | 0.0% |
| 2023 Q2 | 672.1 Million CNY | 0.0% |
| 2023 FY | - CNY | 60.49% |
| 2022 Q4 | 452.42 Million CNY | 0.0% |
| 2022 Q2 | 435.8 Million CNY | 0.0% |
| 2022 FY | - CNY | 25.97% |
| 2021 Q4 | 309.55 Million CNY | 0.0% |
| 2021 FY | - CNY | 13.39% |
| 2021 Q2 | 395.56 Million CNY | 0.0% |
| 2020 FY | - CNY | -7.56% |
| 2020 Q2 | 268.47 Million CNY | 0.0% |
| 2020 Q4 | 353.37 Million CNY | 0.0% |
| 2019 Q2 | 327.82 Million CNY | 0.0% |
| 2019 Q4 | 344.88 Million CNY | 0.0% |
| 2019 FY | - CNY | -2.75% |
| 2018 FY | - CNY | 14.78% |
| 2018 Q4 | 369.24 Million CNY | 0.0% |
| 2018 Q2 | 322.51 Million CNY | 0.0% |
| 2017 Q4 | 325.53 Million CNY | 0.0% |
| 2017 FY | - CNY | -20.24% |
| 2017 Q2 | 277.17 Million CNY | 0.0% |
| 2016 Q2 | 362.18 Million CNY | 0.0% |
| 2016 Q4 | 393.46 Million CNY | 0.0% |
| 2016 FY | - CNY | -2.7% |
| 2015 FY | - CNY | -8.07% |
| 2015 Q2 | 481.16 Million CNY | 0.0% |
| 2015 Q4 | 295.46 Million CNY | 0.0% |
| 2014 Q4 | 372.88 Million CNY | 0.0% |
| 2014 Q2 | 471.95 Million CNY | 0.0% |
| 2014 FY | - CNY | 7.21% |
| 2013 Q4 | 359.38 Million CNY | 0.0% |
| 2013 Q2 | 428.65 Million CNY | 0.0% |
| 2013 FY | - CNY | 4.04% |
| 2012 Q4 | 241.15 Million CNY | 9.39% |
| 2012 Q3 | 220.44 Million CNY | 0.0% |
| 2012 Q2 | 220.44 Million CNY | 0.0% |
| 2012 Q1 | 220.44 Million CNY | 0.0% |
| 2012 FY | - CNY | -25.39% |
| 2011 Q1 | 253.8 Million CNY | 0.0% |
| 2011 Q2 | 253.8 Million CNY | 0.0% |
| 2011 Q3 | 253.8 Million CNY | 0.0% |
| 2011 Q4 | 220.44 Million CNY | -13.14% |
| 2011 FY | - CNY | 1.84% |
| 2010 Q4 | 253.8 Million CNY | -2.84% |
| 2010 Q1 | 261.2 Million CNY | 0.0% |
| 2010 FY | - CNY | 12.87% |
| 2010 Q3 | 261.2 Million CNY | 0.0% |
| 2010 Q2 | 261.2 Million CNY | 0.0% |
| 2009 Q3 | 232.33 Million CNY | 0.0% |
| 2009 FY | - CNY | 84.17% |
| 2009 Q1 | 232.33 Million CNY | 0.0% |
| 2009 Q4 | 261.2 Million CNY | 12.43% |
| 2009 Q2 | 232.33 Million CNY | 0.0% |
| 2008 Q4 | 232.33 Million CNY | 81.42% |
| 2008 FY | - CNY | 19.65% |
| 2008 Q1 | 128.06 Million CNY | 0.0% |
| 2008 Q2 | 128.06 Million CNY | 0.0% |
| 2008 Q3 | 128.06 Million CNY | 0.0% |
| 2007 Q1 | 152 Million CNY | 0.0% |
| 2007 FY | - CNY | 8.18% |
| 2007 Q4 | 128.06 Million CNY | -15.75% |
| 2007 Q3 | 152 Million CNY | 0.0% |
| 2007 Q2 | 152 Million CNY | 0.0% |
| 2006 Q1 | 104.19 Million CNY | 0.0% |
| 2006 FY | - CNY | 5.84% |
| 2006 Q2 | 104.19 Million CNY | 0.0% |
| 2006 Q3 | 104.19 Million CNY | 0.0% |
| 2006 Q4 | 152 Million CNY | 45.89% |
| 2005 Q3 | 92.06 Million CNY | 0.0% |
| 2005 Q2 | 92.06 Million CNY | 0.0% |
| 2005 FY | - CNY | 15.82% |
| 2005 Q4 | 104.19 Million CNY | 13.18% |
| 2005 Q1 | 92.06 Million CNY | 0.0% |
| 2004 Q4 | 92.06 Million CNY | 25.37% |
| 2004 Q1 | 73.43 Million CNY | 0.0% |
| 2004 Q2 | 73.43 Million CNY | 0.0% |
| 2004 Q3 | 73.43 Million CNY | 0.0% |
| 2004 FY | - CNY | 46.55% |
| 2003 FY | - CNY | 0.0% |
| 2003 Q1 | 41.5 Million CNY | 0.0% |
| 2003 Q4 | 73.43 Million CNY | 76.93% |
| 2003 Q3 | 41.5 Million CNY | 0.0% |
| 2003 Q2 | 41.5 Million CNY | 0.0% |
| 2002 Q4 | 41.5 Million CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | -844.21% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | 52.13% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 1196.427% |
| Wai Yuen Tong Medicine Holdings Limited | 113.79 Million HKD | -1147.906% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | 2927.235% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | -1193.109% |
| Essex Bio-Technology Limited | 418.37 Million HKD | -239.429% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | -1753.108% |
| PuraPharm Corporation Limited | -26.16 Million HKD | 5526.619% |
| SSY Group Limited | 2.11 Billion HKD | 32.842% |
| JBM (Healthcare) Limited | 204.39 Million HKD | -594.795% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | -230.315% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 90.797% |